Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Taxane-induced peripheral neuropathy: differences in patient report and objective assessment.

Timmins HC, Li T, Kiernan MC, Baron-Hay S, Marx G, Boyle F, Goldstein D, Park SB.

Support Care Cancer. 2020 Jan 11. doi: 10.1007/s00520-020-05299-y. [Epub ahead of print]


Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.

N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.


Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M.

PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019.


Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Baron-Hay S, Aapro M, Bernareggi A, Schwartzberg L.

Support Care Cancer. 2019 Apr;27(4):1309-1317. doi: 10.1007/s00520-019-4640-8. Epub 2019 Jan 26.


Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.

Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L, Giuffre B, Baron-Hay S, Khasraw M.

Intern Med J. 2018 Jun;48(6):699-705. doi: 10.1111/imj.13617.


Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.

McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB; IN FOCUS Delphi working party.

Support Care Cancer. 2017 Nov;25(11):3485-3493. doi: 10.1007/s00520-017-3772-y. Epub 2017 Jun 7. Review.


Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.

Kandula T, Farrar MA, Kiernan MC, Krishnan AV, Goldstein D, Horvath L, Grimison P, Boyle F, Baron-Hay S, Park SB.

Clin Neurophysiol. 2017 Jul;128(7):1166-1175. doi: 10.1016/j.clinph.2017.04.009. Epub 2017 Apr 25. Review.


Frontline treatment of epithelial ovarian cancer.

Goh J, Mohan GR, Ladwa R, Ananda S, Cohen PA, Baron-Hay S.

Asia Pac J Clin Oncol. 2015 Dec;11 Suppl 6:1-16. doi: 10.1111/ajco.12449. Review.


Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.

Chan A, Shannon C, de Boer R, Baron-Hay S, Redfern A, Bauwens A, Craft P, Webb S, Townsend A, Kotasek D.

Asia Pac J Clin Oncol. 2014 Dec;10(4):368-75. doi: 10.1111/ajco.12292. Epub 2014 Oct 28.


Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?

Khasraw M, Baron-Hay S.

Ann Oncol. 2009 Jul;20(7):1282-3. doi: 10.1093/annonc/mdp305. No abstract available.


Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.

Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM.

J Clin Pathol. 2007 Jun;60(6):622-6. Epub 2006 Jul 5.


A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM.

Br J Cancer. 2006 Mar 27;94(6):904-13.


Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.

Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, Baron-Hay S, Friedlander ML.

Gynecol Oncol. 2006 Feb;100(2):233-8.


Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer.

Baron-Hay S, Boyle F, Ferrier A, Scott C.

Clin Cancer Res. 2004 Mar 1;10(5):1796-806.


Supplemental Content

Loading ...
Support Center